---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-060391"
form_type: "8-K"
ticker: "ADTX"
cik: "0001726711"
company_name: "Aditxt, Inc."
filed_at: "2025-07-01T23:59:59+00:00"
generated_at: "2026-05-18T10:13:23.405452+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aditxt raises $1M in senior notes, invests $925K in Evofem; CEO targets Evofem close by Sept 2025

## Summary
- Issued $1M senior notes (10% interest, maturity Sept 30, 2025) at $800K purchase price (20% original issue discount).
- Purchased $1.42M Evofem convertible note and warrant for $925K; convertible at $0.0154/share, warrant exercisable for 5 years.
- Evofem reported ~$20M revenue in 2024; CEO says pending acquisition target close by end of September 2025, subject to shareholder approval.
- Pearsanta near commercialization (end 2025/Q1 2026) for prostate cancer and endometriosis tests using mitochondrial DNA.
- Adimune autoimmune therapeutic platform still early stage; described as 'sleeping giant'; retraining immune system approach.

## SEC filing metadata
- accession: 0001213900-25-060391
- form_type: 8-K
- ticker: ADTX
- cik: 0001726711
- company_name: Aditxt, Inc.
- filed_at: 2025-07-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1726711/000121390025060391/0001213900-25-060391-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1726711/000121390025060391/ea0247298-8k_aditxt.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-060391
- JSON: https://secwatch.observer/filing/0001213900-25-060391.json
- Plain text: https://secwatch.observer/filing/0001213900-25-060391.txt

## Key facts
- Debt Financings
  Aditxt, Inc. incurred senior notes of $1,000,000 aggregate original principal amount with accredited investors at 10% per annum maturing September 30, 2025.
  - Instrument: senior notes
  - Principal: $1,000,000 aggregate original principal amount
  - Counterparty: accredited investors
  - Rate: 10% per annum
  - Maturity: September 30, 2025
  - Event: incurrence
  source text: On June 26, 2025, Aditxt, Inc. (the “ Company ”) issued and sold senior notes (each, a “ Note ”) to accredited investors in the aggregate original principal amount of $1,000,000 for a purchase price of $800,000, reflecting an aggregate original issue discount of $200,000. The Notes bear interest at a rate of 10% per annum and have a maturity date of September 30, 2025 (the “ Maturity Date ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1726711/000121390025060391/0001213900-25-060391-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.